



Bydureon® (exenatide) Pen – Product discontinuation

- On September 14, 2020, [AstraZeneca announced](#) that [Bydureon \(exenatide\) Pen](#) will be discontinued as of March 2021 due to business reasons.
 - The discontinuation is not due to safety or efficacy issues, product quality or manufacturing concerns.
- [Bydureon BCise® \(exenatide\) Pen](#) will continue to be available.
- Bydureon and Bydureon BCise are both indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
 - Unlike Bydureon, the Bydureon BCise formulation is an auto-injector that does not need to be titrated or reconstituted. It has a pre-attached hidden needle and contains the same active ingredient as Bydureon pen.
- Patients can continue to use their existing Bydureon Pen until their supply runs out, but they will need to eventually switch over to the Bydureon BCise Pen once the old device is no longer available.
- When switching patients from Bydureon to Bydureon BCise, health care providers need to write a new prescription for Bydureon BCise.
- Patients should not use Bydureon Pen and Bydureon BCise at the same time. Patients should start Bydureon BCise on their next regularly scheduled Bydureon Pen dosing day.
- Per AstraZeneca, there is adequate supply of Bydureon BCise and there are no anticipated supply issues when patients switch from Bydureon Pen to Bydureon BCise.
- AstraZeneca is committed to reaching out to as many current Bydureon Pen patients as possible. AstraZeneca is providing direct-to-pharmacist messaging as well, communicating via multiple health care provider and consumer marketing channels to ensure that patients have multiple ways of learning about this change in addition to hearing it from their health care provider.
- For more information regarding the discontinuation of Bydureon Pen contact AstraZeneca by phone at **1-844-929-3736**, visit their website at www.bydureonhcp.com or contact [AstraZeneca Medical Information](#).



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at optum.com.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.